US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Mega Cap ETF

248.23

-3.9200-1.55%

Post-market: 248.580.3500+0.14%16:23 EST

Volume:107.12K

Turnover:26.79M

Market Cap:9.37B

PE:- -

High:253.15

Open:252.99

Low:248.00

Close:252.15

52wk High:255.75

52wk Low:173.32

Shares:37.76M

Float Shares:37.76M

Volume Ratio:1.30

T/O Rate:0.28%

Dividend:2.32

Dividend Rate:0.94%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

ChatGPT Thinks GLD Will Trade At This Price By March 20, And You Can Trade With Leverage After One Evaluation

Benzinga_recent_news

Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Shanghai Ship Design & Research Institute Expands Green Vessel Portfolio, Leading in Alternative Fuel Sector

SDARI Achieves Record High in New Ship Design Orders for First Three Quarters

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MGC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MGC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MGC\",,,,,undefined,":{"symbol":"MGC","market":"US","secType":"STK","nameCN":"Vanguard Mega Cap ETF","latestPrice":248.23,"timestamp":1770930000000,"preClose":252.15,"halted":0,"volume":107124,"hourTrading":{"tag":"盘后","latestPrice":248.58,"preClose":248.23,"latestTime":"16:23 EST","volume":23,"amount":5708.019020000001,"timestamp":1770931382218,"change":0.35,"changeRate":0.00141,"amplitude":0.003975},"delay":0,"changeRate":-0.015546301804481522,"floatShares":37759267,"shares":37759267,"eps":0,"marketStatus":"Post-Mkt","change":-3.92,"latestTime":"02-12 16:32:30 EST","open":252.99,"high":253.15,"low":248,"amount":26790672.17578,"amplitude":0.020424,"askPrice":269.98,"askSize":100,"bidPrice":226.48,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770944400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":252.15,"sharesOutstanding":37759267,"nav":252.36,"aum":9528928620.12,"dividendRate":0.009351,"bidAskSpread":0.000277,"preHourTrading":{"tag":"盘前","latestPrice":252.15,"preClose":252.15,"latestTime":"08:10 EST","volume":112,"amount":28241.155039999998,"timestamp":1770901856035,"change":0,"changeRate":0,"amplitude":0.001172},"postHourTrading":{"tag":"盘后","latestPrice":248.58,"preClose":248.23,"latestTime":"16:23 EST","volume":23,"amount":5708.019020000001,"timestamp":1770931382218,"change":0.35,"changeRate":0.00141,"amplitude":0.003975},"volumeRatio":1.304866,"impliedVol":0.1711,"impliedVolPercentile":0.8008},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MGC\",,,,,undefined,":{"symbol":"MGC","floatShares":37759267,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.304866,"shares":37759267,"dividePrice":2.3213,"high":253.15,"amplitude":0.020424,"preClose":252.15,"low":248,"week52Low":173.32,"pbRate":"--","week52High":255.75,"institutionHeld":0,"latestPrice":248.23,"eps":0,"divideRate":0.009351,"volume":107124,"delay":0,"ttmEps":0,"open":252.99,"prevYearClose":251.17,"prevWeekClose":252.02,"prevMonthClose":253.59,"prevQuarterClose":251.17,"fiveDayClose":247.39,"twentyDayClose":252.76,"sixtyDayClose":247.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MGC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"MGC","amount":0.5968,"announcedDate":"2025-12-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Vanguard Mega Cap ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-29","symbol":"MGC","amount":0.5801,"announcedDate":"2025-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-29","defaultRemindTime":1759152600000,"name":"Vanguard Mega Cap ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-01","payableDate":"2025-09-29","currency":"USD","dateTimestamp":1759118400000,"payDate":"2025-10-01"},{"date":"2025-06-30","symbol":"MGC","amount":0.5517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-30","defaultRemindTime":1751290200000,"name":"Vanguard Mega Cap ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-02","payableDate":"2025-06-30","currency":"USD","dateTimestamp":1751256000000,"payDate":"2025-07-02"},{"date":"2025-03-27","symbol":"MGC","amount":0.5985,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Vanguard Mega Cap ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"MGC","amount":0.628,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Vanguard Mega Cap ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MGC\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-21","recordDate":"2016-03-23","paymentDate":"2016-03-28","value":0.369,"currency":"USD"},{"executeDate":"2016-06-21","recordDate":"2016-06-23","paymentDate":"2016-06-27","value":0.368,"currency":"USD"},{"executeDate":"2016-09-20","recordDate":"2016-09-22","paymentDate":"2016-09-26","value":0.422,"currency":"USD"},{"executeDate":"2016-12-20","recordDate":"2016-12-22","paymentDate":"2016-12-27","value":0.471,"currency":"USD"},{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-04","value":0.338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MGC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MGC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610312652","title":"ChatGPT Thinks GLD Will Trade At This Price By March 20, And You Can Trade With Leverage After One Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2610312652","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610312652?lang=en_us&edition=fundamental","pubTime":"2026-02-10 00:01","pubTimestamp":1770652860,"startTime":"0","endTime":"0","summary":"Gold has been one of the most volatile major assets of the past year.After surging to record highs on central bank buying, prices reversed sharply as rate expectations shifted, then rebounded again on renewed geopolitical risk. In just the past few months, gold has swung through multiple double-digit percentage moves, frustrating long-term holders and rewarding short-term traders who caught the turns.That volatility has been reflected directly in the SPDR Gold Shares ETF , which has whipsawed between sharp rallies and deep pullbacks as investors struggle to price where inflation, rates, and global risk ultimately settle.For traders, that environment creates opportunity. For investors, it creates uncertainty.If you're trying to time entries and exits, you're thinking about where gold is headed next.The AI agent was fed recent price action, momentum indicators, volatility data, and macro inputs to generate a short-term outlook through March 20.At the time of the run, GLD was trading at $","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/09/Investment-In-Gold-Involves-Allocating-F.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/09/Investment-In-Gold-Involves-Allocating-F.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/topics/26/02/50484376/chatgpt-thinks-gld-will-trade-at-this-price-by-march-20-and-you-can-trade-with-leverage-after-one-evaluation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/topics/26/02/50484376/chatgpt-thinks-gld-will-trade-at-this-price-by-march-20-and-you-can-trade-with-leverage-after-one-evaluation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["GLDM","IAU","UGL","MGC","BK4535","BK4585","GDXJ","BK4504","GLL","GDX","BK4588","XME","SGOL"],"gpt_icon":0},{"id":"2586628532","title":"Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2586628532","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586628532?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:06","pubTimestamp":1764119160,"startTime":"0","endTime":"0","summary":"SINGAPORE, Nov. 26, 2025 /PRNewswire/ --Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization of Tuznue  across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.Tuznue is a biosimilar to Herceptin , approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received European Commission  marketing authorization for Tuznue in September 2024. This approval marks a major milestone for the company's biosimilar portfolio, signaling progress in expanding access to cost-effective treatments across key global markets.Under the agreement, Biosidus secures exclusive rights to market and distribute Tuznue in Argentina, Mexico, Bolivia, and Paraguay, leveraging its exte","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-and-biosidus-enter-exclusive-license-agreement-for-tuznue-commercialization-in-latin-america-302626222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","MBC","BK4211","MGC.AU","EBC","BK4086","PBH","BK4007","MGC","BK4201"],"gpt_icon":1},{"id":"2581709464","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709464","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709464?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:01","pubTimestamp":1762376460,"startTime":"0","endTime":"0","summary":"Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living , Quantitative Myasthenia Gravis , and other efficacy measures at Week 13 in Phase 2 MaGic trial in gMG. New claseprubart data from the MaGic open-label extension supporting potential for 300mg/2mL Q4W dosing and new in vitro data highlighting potential efficacy benefits of upstream  vs. downstream  complement inhibition were presented during the AANEM Annual Meeting in October 2025. Phase 3 gMG trial including two claseprubart treatment arms, 300mg/2mL Q2W and 300mg/2mL Q4W, vs. placebo anticipated to initiate in 2026. Accelerated timing for interim responder analysis for Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy ; now anticipated in Q2'26  due to faster than expected enrollment. Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy  ongoing; top-line results anticipated in 2H'26. Annou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGC","BK4539","DNTH","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"1132487004","title":"Shanghai Ship Design & Research Institute Expands Green Vessel Portfolio, Leading in Alternative Fuel Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1132487004","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132487004?lang=en_us&edition=fundamental","pubTime":"2025-11-04 09:20","pubTimestamp":1762219249,"startTime":"0","endTime":"0","summary":"On November 4, it was reported that China State Shipbuilding Corporation (CSSC) announced that its subsidiary, Shanghai Ship Design & Research Institute (SDARI), has taken the lead in developing...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251142724.SGD","LU0742534661.SGD","MGC","LU0345780950.USD","BK4144","LU0048573561.USD","LU2449327464.USD","LNG","LU0788109394.HKD","BK4088","LU0345770308.USD","IE00B29SXK94.USD","LU0122376428.USD","LU0630314457.HKD","LU0314104364.USD","LU0368265418.SGD","LU0170899867.USD","CCS","LU0345781412.USD","LU0251131958.USD","LU0345770993.USD","IE00B29SXL02.USD"],"gpt_icon":0},{"id":"1128813262","title":"SDARI Achieves Record High in New Ship Design Orders for First Three Quarters","url":"https://stock-news.laohu8.com/highlight/detail?id=1128813262","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128813262?lang=en_us&edition=fundamental","pubTime":"2025-11-01 15:00","pubTimestamp":1761980457,"startTime":"0","endTime":"0","summary":"Shanghai Ship Design is making waves in the global shipbuilding market. Over the past two years, Shanghai Ship Research and Design Institute (SDARI), under China State Shipbuilding Corporation, has...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B29SXL02.USD","LU0251142724.SGD","LU0368265418.SGD","LU0170899867.USD","BK4144","IE00B29SXK94.USD","IMO","BK4157","LU0314104364.USD","LU0251131958.USD","LU0630314457.HKD","LU0345780950.USD","LNG","LU0122376428.USD","LU0788109394.HKD","BK6511","LU2449327464.USD","BK4201","MASS","MGC","LU0742534661.SGD","LU0345781412.USD","LU0345770993.USD","BK6092","LU0048573561.USD","LU0345770308.USD","5RE.SI"],"gpt_icon":0},{"id":"2565683209","title":"Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2565683209","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565683209?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:00","pubTimestamp":1757329200,"startTime":"0","endTime":"0","summary":"Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/08/3145988/0/en/Dianthus-Therapeutics-Announces-Positive-Data-for-Claseprubart-DNTH103-from-the-Phase-2-MaGic-Trial-in-Generalized-Myasthenia-Gravis-Supporting-Its-Potential-Best-In-Class-Profile.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MGC","BK4539","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}